Veru Inc (VERU) USD0.01
$0.0186
(2.87%)
- Add to watchlist
- This stock can be held in a
$0.0186
(2.87%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.0186
(2.87%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs: obesity-enobosarm in combination with GLP-1 RA to augment fat loss, to prevent muscle loss, and maintain physical function for higher quality weight loss, and breast cancer-enobosarm plus abemaciclib for the second line treatment of androgen receptor positive, estrogen receptor positive and others. Sabizabulin, a microtubule disruptor, is being developed for the treatment of hospitalized patients with viral-induced ARDS. It also has an FDA-approved commercial product, FC2 Female Condom (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections.
Contact details
Important dates
General stock information
- Short code:
- VERU
- ISIN:
- US92536C1036
- Market cap:
- $91.99 million
- Shares in issue:
- 146.38 million
- Sector:
- Personal Care Products
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.